Lifespan Vision Leads Remedium Bio Series A

Lifespan Vision Ventures announced it is leading a $10 million Series A financing for Remedium Bio, Inc., a biotechnology company developing durable protein therapeutics. The round's initial closing has been completed with participation from Eli Lilly and Company and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures joined Remedium's Board of Directors. The funds will support advancement of Remedium's lead programs, platform expansion, and preparation for first-in-human clinical studies. Remedium's platform aims to enable controlled, long-lasting expression of therapeutic proteins via subcutaneous administration, potentially providing multi-year benefit for chronic diseases. The financing follows recent progress across Remedium's pipeline and strategic collaborations.